Logo
x

Search

Subscribe Now

esophageal squamous cell carcinoma

Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

  • September 23, 2021
Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021

Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamo...

  • September 17, 2021
BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell...

  • August 17, 2021
Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell...

  • July 30, 2021
BeiGene’s Evimbra (tislelizumab) Receives EC’s Approval for Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    BeiGene’s Evimbra (tislelizumab) Receives EC’s Approval for Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell...

    • September 19, 2023
    BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

      BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous...

      • July 21, 2023
      Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at ASCO 2023

        Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at A...

        • June 8, 2023
        Innovent Presents Final Analysis P-III Study (ORIENT-15) Results of Sintilimab as 1L Treatment of Esophageal Squamous Cell Carcinoma at AACR 2023

          Innovent Presents Final Analysis P-III Study (ORIENT-15) Results of Sintilimab as 1L Treatment of Esophageal Squamous Cell Carcino...

          • April 17, 2023
          Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea

            Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Ce...

            • March 23, 2023
            CStone Reports P-III Study (GEMSTONE-304) Results of Sugelimab as 1L Treatment of Esophageal Squamous Cell Carcinoma

              CStone Reports P-III Study (GEMSTONE-304) Results of Sugelimab as 1L Treatment of Esophageal Squamous Cell Carcinoma

              • January 3, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.